Abstract
A variety of mechanisms of crizotinib resistance have been defined in patients with ALK-rearranged lung cancer who no longer have a response to the drug. A case is presented in which the tumor lost the rearrangement and mutations developed in several other genes.
Cite
CITATION STYLE
APA
Giri, S., Patel, J. K., & Mahadevan, D. (2014). Novel Mutations in a Patient with ALK -Rearranged Lung Cancer. New England Journal of Medicine, 371(17), 1655–1656. https://doi.org/10.1056/nejmc1410799
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for free